Brokers Issue Forecasts for Genmab A/S FY2029 Earnings

Genmab A/S (NASDAQ:GMAB - Free Report) - Analysts at William Blair issued their FY2029 EPS estimates for Genmab A/S in a report released on Monday, March 10th. William Blair analyst M. Phipps forecasts that the company will post earnings of $4.38 per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

GMAB has been the subject of a number of other research reports. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Truist Financial cut their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Finally, Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus target price of $41.33.

Remove Ads

Genmab A/S Trading Up 1.4 %

Shares of NASDAQ:GMAB traded up $0.29 during trading on Thursday, reaching $20.80. The company had a trading volume of 1,768,667 shares, compared to its average volume of 905,576. The company has a fifty day moving average of $21.24 and a two-hundred day moving average of $22.38. The stock has a market capitalization of $13.76 billion, a P/E ratio of 11.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.02.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC boosted its stake in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC boosted its stake in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the period. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.